REG3A and pancreatic adenocarcinoma: In order to search biomarkers for pancreatic cancer that can facilitate to monitor treatment efficacy or early detection, Porterfield et al. (22) performed an in-depth LC-MS/MS analysis of the proteome in pancreatic ductal fluid from normal and pancreatic adenocarcinoma patients, and Reg3A was found increased in cancer ductal fluid compared to normal.